BI 416970Alternative Names: BI-416970
Latest Information Update: 28 Apr 2016
At a glance
- Originator Boehringer Ingelheim
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 28 Apr 2016 Phase-I development is ongoing in Germany
- 20 Mar 2014 Preclinical trials in Undefined indication in Germany (PO, tablet; PO, liquid)
- 20 Mar 2014 Boehringer Ingelheim plans a phase I trial for Healthy volunteers in Germany (NCT02093819)